Security key
690469101
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 61,768,473
- Total 13F value
- $100,169,419
- Share change
- +33,214,060
- Put/Call ratio
- 25%
- SEC-reported price per share
- $1.63
- Number of holders
- 83
- Value change
- +$54,659,119
- Number of buys
- 44
- Number of sells
- 35
- Shares outstanding
- 186,597,793
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
83
Top holders
10
OVID full security history
Ownership snapshot
Full 13F holder table
Ovid Therapeutics Inc. SEC filings
Ovid Therapeutics Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of OVID - Ovid Therapeutics Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
TAKEDA PHARMACEUTICAL CO LTD
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
15/15
Latest evidence
31 Dec 2025
13D/G
3/4/5
13F
Lead comparable stake: 12%
13D/G row: TAKEDA PHARMACEUTICAL CO LTD
Showing 1-6 of 15 holder rows.
Quick read
TAKEDA PHARMACEUTICAL CO LTD leads the comparable SEC ownership view at 12%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens TAKEDA PHARMACEUTICAL CO LTD's linked filing trail.
Comparable ownership
Top 5
TAKEDA PHARMACEUTICAL CO LTD
12%
Janus Henderson Group Ltd.
10%
RA CAPITAL MANAGEMENT, L.P.
9.9%
ADAR1 Capital Management, LLC
6.9%
Madison Avenue Partners, LP
4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| TAKEDA PHARMACEUTICAL CO LTD |
13D/G
3/4/5
13F
Takeda Pharmaceutical Company Limited · 10%+ Owner · Company
|
12%
|
$11,680,055
8,781,996 shares
|
$0 | 08 Dec 2025 |
| Janus Henderson Group Ltd. |
13D/G
JANUS HENDERSON GROUP PLC
|
10%
|
$9,461,772
7,114,114 shares
|
$0 | 28 Nov 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
|
9.9%
|
$19,889,602
13,259,735 shares
|
$0 | 11 Dec 2025 |
| ADAR1 Capital Management, LLC |
13D/G
13F
Company
|
6.9%
|
$14,111,932
9,284,166 shares
|
$0 | 31 Dec 2025 |
| Madison Avenue Partners, LP |
13D/G
|
4%
|
$969,800
2,852,352 shares
|
$0 | 31 Dec 2024 |
| Rubric Capital Management LP |
13D/G
|
0.67%
|
$153,131
478,533 shares
|
$0 | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
83
Shares
61,768,473
Rows available
83
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
80
Q4 2025 holders
83
Holder diff
3
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|